Shu S - Search Results

1

Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.

Kuriyama H, Watanabe S, Kjaergaard J, Tamai H, Zheng R, Weinberg AD, Hu HM, Cohen PA, Plautz GE, Shu S. Kuriyama H, et al. Among authors: shu s. Cell Immunol. 2006 Sep;243(1):30-40. doi: 10.1016/j.cellimm.2006.11.002. Epub 2007 Jan 17. Cell Immunol. 2006. PMID: 17207783

2

Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.

Plautz GE, Inoue M, Shu S. Plautz GE, et al. Among authors: shu s. Cell Immunol. 1996 Aug 1;171(2):277-84. doi: 10.1006/cimm.1996.0204. Cell Immunol. 1996. PMID: 8806798

3

Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.

Plautz GE, Touhalisky JE, Shu S. Plautz GE, et al. Among authors: shu s. Cell Immunol. 1997 Jun 15;178(2):101-7. doi: 10.1006/cimm.1997.1140. Cell Immunol. 1997. PMID: 9225000

4

Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells.

Mukai S, Kagamu H, Shu S, Plautz GE. Mukai S, et al. Among authors: shu s. Cell Immunol. 1999 Mar 15;192(2):122-32. doi: 10.1006/cimm.1998.1439. Cell Immunol. 1999. PMID: 10087180

5

Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Kjaergaard J, et al. Among authors: shu s. Cancer Res. 2000 Oct 1;60(19):5514-21. Cancer Res. 2000. PMID: 11034096

6

Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.

Plautz GE, Mukai S, Cohen PA, Shu S. Plautz GE, et al. Among authors: shu s. J Immunol. 2000 Oct 1;165(7):3656-62. doi: 10.4049/jimmunol.165.7.3656. J Immunol. 2000. PMID: 11034369

7

Tumor-dendritic cell fusion technology and immunotherapy strategies.

Shu S, Cohen P. Shu S, et al. J Immunother. 2001 Mar-Apr;24(2):99-100. J Immunother. 2001. PMID: 11265778 No abstract available.

8

Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.

Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S. Kjaergaard J, et al. Among authors: shu s. J Immunol. 2001 Dec 1;167(11):6669-77. doi: 10.4049/jimmunol.167.11.6669. J Immunol. 2001. PMID: 11714839

9

Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.

Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, Shu S. Kuriyama H, et al. Among authors: shu s. Dev Biol (Basel). 2004;116:169-78; discussion 179-86. Dev Biol (Basel). 2004. PMID: 15603192

10

Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion.

Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, Shu S. Hayashi T, et al. Among authors: shu s. Clin Immunol. 2002 Jul;104(1):14-20. doi: 10.1006/clim.2002.5224. Clin Immunol. 2002. PMID: 12139943

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,458 results

Search Page

Filters